While lithium is typically considered just a treatment for mental health conditions, evidence has slowly been building suggesting protective effects against cancer. An early study explored the rates of cancer in patients with mental health conditions with and without a history of lithium use. They found psychiatric patients on lithium had a 10% lower risk of cancer than psychiatric patients without. They also saw trends towards reduced cancer with increasing lithium intake (Cohen 1998).

A more recent Swedish study found that bipolar patients had much greater risks for cancers of the respiratory, digestive and endocrine systems. Risks for these cancers were 1.47, 1.72 and 2.6 times higher, respectively. However, patients with bipolar disorder that were on lithium had these cancer risks reduced back to the level of the standard population (Martinsson 2016). A similar study out of Taiwan compared bipolar patients on lithium to those on anticonvulsants. They found a 27% reduction in risk of cancer with lithium, noting that the higher the dose, the greater the reduction in cancer risk (Huang 2016).

Lithium and Cancer: Potential Mechanisms

Targets of Lithium

For all its complexity, there are only a few confirmed targets of lithium that show enzyme inhibition and biological consequences at achievable lithium concentrations: inositol monophosphatase and the related magnesium-dependent phosphomonoesterases and glycogen synthase kinase-3 (GSK-3) (Hallcher 1980, Phiel 2001). These enzymes all have a magnesium binding site, and lithium, with an ionic radius similar to magnesium, appears to block magnesium binding, inhibiting the enzymes.


Probably the best studied of these enzymes is GSK-3. GSK-3 is a protein kinase that phosphorylates other proteins. It was initially discovered to phosphorylate the enzyme glycogen synthase, which inhibits the production of glycogen. Lithium, by decreasing GSK-3 activity, promotes glycogen production. This has been shown repeatedly in cellular studies that found increased glycogen in liver, muscle and white blood cells in response to lithium (Rodriguez-Gil 1993, Furnsinn 1997, Choi 2000).

And while GSK-3 phosphorylates glycogen synthase, it also has multiple other targets as well. GSK-3 can phosphorylate Wnt signaling β-catenin, genetic transcription factors, RNA splicing factors, translation regulators, protein kinases, and cytoskeletal proteins. Due to the diversity of its targets, GSK-3 has been described as potentially regulating every aspect of cellular function (Sutherland 2011).

GSK-3 and Cancer

Of relevance to cancer are the effects of lithium on GSK-3, cellular signalling pathways, and resulting changes in oncogenes. The Wnt signalling pathway and the hedgehog signalling pathway are both relevant to cancer and regulated by GSK-3. As such, lithium can influence both pathways by decreasing GSK-3 activity.

The Wnt Signaling Pathway

GSK-3 phosphorylates Wnt signalling pathway β-catenin. Phosphorylation targets β-catenin for destruction and elimination. β-catenin activates target genes, including the oncogene MYC. When GSK-3 is inhibited by lithium, β-catenin levels increase and MYC is more strongly activated.

While MYC is considered an oncogene, it has both pro and anticarcinogenic activity. In lower levels, MYC can promote cancer. At higher levels it has anticancer activity, helping promote apoptosis of cancer cells (Harrington 2019). GSK-3 inhibitors, like lithium, increase levels of MYC, helping increase its anticarcinogenic effects to inhibit cancer cells (Kotliarova 2008).

The Hedgehog Signaling Pathway

Interestingly, research shows that lithium has opposite, suppressive effects on other oncogenes that are associated with the hedgehog signalling pathway. The hedgehog signalling pathway is involved in fetal development, cellular growth and cellular reproduction. It has been implicated in a number of cancers as well. In response to lithium, the pathway has a biphasic response. The key signalling protein glioma-associated oncogene homolog 1 (GLI1) initially increases, then decreases over time. With decreased GLI1, the hedgehog signalling pathway is inhibited overall. Decreased activation of the hedgehog pathway interrupts cell cycle progression, replication and induces apoptosis in cancer cells. These effects are tied to decreased activity of a number of different oncogenes influenced by the pathway (Ma 2019, Peng 2013).

Lithium and Cancer In-Vitro

Preclinical work exploring the effects of lithium on cancer cells shows distinct promise. Lithium has been shown to increase apoptosis in numerous cancer cell lines, including choroidal melanoma, pancreas, liver, non-small cell lung, leukemia, head and neck squamous cell and stomach cancers (Zhang 2021, Li 2015, Lan 2013, Zubcic 2020, Wu 2018). For treatment, most of the research focuses on lithium as an adjunctive therapy in combination with other cancer therapies to increase cancer cell death and improve overall survival.

Lithium and Cancer In-Vivo

Early work with glioblastoma has shown potential benefits. Glioblastomas are aggressive brain tumors with an average life expectancy of less than two years. Increased GSK-3 activity also correlates with worse outcomes. A drug cocktail, including lithium, was trialled in seven glioblastoma patients and demonstrated increased survival (Furuta 2017).

However, a separate clinical trial, exploring the effects of lithium on low-grade neuroendocrine tumors did not find benefits and enrollment was discontinued early with only 13 patients receiving treatment (Lubner 2011). Other clinical trials with lithium and cancer are ongoing. Hopefully, with more research, we can expand our understanding of lithium and its potential use in cancer treatment.


Lithium has potential benefits for modulating signaling pathways related to several oncogenes that are relevant to cancer. While research is ongoing, the use of lithium as an adjunctive therapy to improve cancer outcomes is still in the very early stages with a need for a better understanding of the dynamics and complexities of lithium’s actions. With more research, lithium may take its place alongside other therapies as an adjunctive treatment for cancer.


Cohen Y, Chetrit A, Cohen Y, Sirota P, Modan B. Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol. 1998 Apr;15(1):32-6. doi: 10.1007/BF02787342. PMID: 9643528.

Martinsson L, Westman J, Hällgren J, Ösby U, Backlund L. Lithium treatment and cancer incidence in bipolar disorder. Bipolar Disord. 2016;18(1):33-40. doi:10.1111/bdi.12361

Huang RY, Hsieh KP, Huang WW, Yang YH. Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study. Br J Psychiatry. 2016;209(5):393-399. doi:10.1192/bjp.bp.116.181362

Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem. 1980;255(22):10896-10901.

Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol. 2001;41:789-813. doi:10.1146/annurev.pharmtox.41.1.789

Rodriguez-Gil JE, Guinovart JJ, Bosch F. Lithium restores glycogen synthesis from glucose in hepatocytes from diabetic rats. Arch Biochem Biophys. 1993;301(2):411-415. doi:10.1006/abbi.1993.1164

Fürnsinn C, Noe C, Herdlicka R, et al. More marked stimulation by lithium than insulin of the glycogenic pathway in rat skeletal muscle. Am J Physiol. 1997;273(3 Pt 1):E514-E520. doi:10.1152/ajpendo.1997.273.3.E514

Choi WS, Sung CK. Effects of lithium and insulin on glycogen synthesis in L6 myocytes: additive effects on inactivation of glycogen synthase kinase-3. Biochim Biophys Acta. 2000;1475(3):225-230. doi:10.1016/s0304-4165(00)00068-4

Sutherland C. What Are the bona fide GSK3 Substrates?. Int J Alzheimers Dis. 2011;2011:505607. doi:10.4061/2011/505607

Harrington CT, Sotillo E, Robert A, et al. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma [published correction appears in Leukemia. 2019 Nov 22;:. Klein, Peter [corrected to Klein, Peter S]]. Leukemia. 2019;33(10):2429-2441. doi:10.1038/s41375-019-0454-4

Kotliarova S, Pastorino S, Kovell LC, et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res. 2008;68(16):6643-6651. doi:10.1158/0008-5472.CAN-08-0850

Ma Y, Hu X, Shang C, Zhong M, Guo Y. Silencing of long non-coding RNA CCAT2 depressed malignancy of oral squamous cell carcinoma via Wnt/β-catenin pathway [published correction appears in Tumour Biol. 2019 May;41(5):1010428319845757]. Tumour Biol. 2017;39(7):1010428317717670. doi:10.1177/1010428317717670

Peng Z, Ji Z, Mei F, Lu M, Ou Y, Cheng X. Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway. PLoS One. 2013;8(4):e61457. Published 2013 Apr 23. doi:10.1371/journal.pone.0061457

Zhang Q, Zhang Q, Li H, Zhao X, Zhang H. LiCl induces apoptosis via CHOP/NOXA/Mcl-1 axis in human choroidal melanoma cells. Cancer Cell Int. 2021;21(1):96. Published 2021 Feb 8. doi:10.1186/s12935-021-01778-2

Li L, Song H, Zhong L, et al. Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta. Int J Med Sci. 2015;12(10):805-810. Published 2015 Sep 20. doi:10.7150/ijms.12429

Lan Y, Liu X, Zhang R, Wang K, Wang Y, Hua ZC. Lithium enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells. Biometals. 2013;26(2):241-254. doi:10.1007/s10534-012-9607-x

Zubčić V, Rinčić N, Kurtović M, et al. GANT61 and Lithium Chloride Inhibit the Growth of Head and Neck Cancer Cell Lines Through the Regulation of GLI3 Processing by GSK3β. Int J Mol Sci. 2020;21(17):6410. Published 2020 Sep 3. doi:10.3390/ijms21176410

Wu YY, Hsieh CT, Chiu YM, et al. GSK-3 inhibitors enhance TRAIL-mediated apoptosis in human gastric adenocarcinoma cells. PLoS One. 2018;13(12):e0208094. Published 2018 Dec 17. doi:10.1371/journal.pone.0208094

Furuta T, Sabit H, Dong Y, et al. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Oncotarget. 2017;8(14):22811-22824. doi:10.18632/oncotarget.15206

Lubner SJ, Kunnimalaiyaan M, Holen KD, et al. A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist. 2011;16(4):452-457. doi:10.1634/theoncologist.2010-0323